Key Takeaways INSM shares surged on FDA approval of Brinsupri, the first NCFB treatment, with rapid early uptake.Insmed's Brinsupri posted $28.1M in Q3 revenues, reinforcing its multi-billion-dollar potential.Insmed's Arikayce sales climbed 21% YoY, prompting a full-year revenue guidance upgrade to $420$430M.Insmed’s (INSM) shares have surged 78% over the past six months, driven by strong momentum around its late-stage pipeline and robust sales from its marketed drugs, boosting investor confidence.The prima ...